Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenna D Goldberg

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Expert Review of Hematology|February 5, 2013
Assessing response of therapy for acute and chronic graft-versus-host diseaseJenna D Goldberg, Sergio Giralt
Transplantation|August 31, 2010
Rapid engraftment at a cost?Jenna D Goldberg, Georgia B Vogelsang
The New England Journal of Medicine|November 2, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma. ReplyPhilippe Moreau, Suzette Girgis, Jenna D Goldberg
Journal of Pediatric Hematology/Oncology|July 9, 2003
Pentostatin for the treatment of chronic graft-versus-host disease in childrenJenna D Goldberg, David A Jacobsohn, Jeffrey Margolis, et al.
Journal of Cellular and Molecular Medicine|November 21, 2013
Clinical applications of palifermin: amelioration of oral mucositis and other potential indicationsSaroj Vadhan-Raj, Jenna D Goldberg, Miguel-Angel Perales, et al.
Cancer Reports (Hoboken, N.J.)|February 15, 2022
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapiesRebecca Crawford, Katharine S Gries, Satish Valluri, et al.
Leukemia & Lymphoma|June 11, 2014
Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplantIzaskun Ceberio, Sean M Devlin, Craig Sauter, et al.
British Journal of Haematology|August 24, 2017
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studiesSimon Rule, Martin Dreyling, Andre Goy, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 4, 2024
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamabMarie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, et al.
Blood Advances|August 25, 2022
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Expert Review of Hematology|February 5, 2013
Assessing response of therapy for acute and chronic graft-versus-host diseaseJenna D Goldberg, Sergio Giralt
Transplantation|August 31, 2010
Rapid engraftment at a cost?Jenna D Goldberg, Georgia B Vogelsang
The New England Journal of Medicine|November 2, 2022
Teclistamab in Relapsed or Refractory Multiple Myeloma. ReplyPhilippe Moreau, Suzette Girgis, Jenna D Goldberg
Journal of Pediatric Hematology/Oncology|July 9, 2003
Pentostatin for the treatment of chronic graft-versus-host disease in childrenJenna D Goldberg, David A Jacobsohn, Jeffrey Margolis, et al.
Journal of Cellular and Molecular Medicine|November 21, 2013
Clinical applications of palifermin: amelioration of oral mucositis and other potential indicationsSaroj Vadhan-Raj, Jenna D Goldberg, Miguel-Angel Perales, et al.
Cancer Reports (Hoboken, N.J.)|February 15, 2022
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapiesRebecca Crawford, Katharine S Gries, Satish Valluri, et al.
Leukemia & Lymphoma|June 11, 2014
Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplantIzaskun Ceberio, Sean M Devlin, Craig Sauter, et al.
British Journal of Haematology|August 24, 2017
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studiesSimon Rule, Martin Dreyling, Andre Goy, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 4, 2024
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamabMarie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, et al.
Blood Advances|August 25, 2022
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Pageof 4